Sector
PharmaceuticalsOpen
₹306Prev. Close
₹309Turnover(Lac.)
₹16.1Day's High
₹309.95Day's Low
₹30352 Week's High
₹40352 Week's Low
₹255Book Value
₹157.17Face Value
₹10Mkt Cap (₹ Cr.)
311.71P/E
46.47EPS
6.65Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 9.33 | 9.28 | 7.01 | 6.23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 122.53 | 114.78 | 76.04 | 55.9 |
Net Worth | 131.86 | 124.06 | 83.05 | 62.13 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 79.51 | 61.55 | 54.75 | 53.64 |
yoy growth (%) | 29.17 | 12.41 | 2.07 | -13.55 |
Raw materials | -37.42 | -28.03 | -23.8 | -24.22 |
As % of sales | 47.07 | 45.53 | 43.47 | 45.15 |
Employee costs | -8.04 | -6.99 | -6.2 | -5.96 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 7.01 | 1.37 | 1.68 | 0.9 |
Depreciation | -4.3 | -4.12 | -4.33 | -4.31 |
Tax paid | -2.24 | -0.51 | -0.57 | 0.31 |
Working capital | 7.22 | -0.8 | 0.64 | -0.44 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 29.17 | 12.41 | 2.07 | -13.55 |
Op profit growth | 106.65 | -1.93 | 8.47 | -47.49 |
EBIT growth | 245.43 | 12.95 | 27.61 | -77.4 |
Net profit growth | 710.1 | -22.82 | 76.96 | -85.52 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 155.42 | 172.37 | 135.07 | 79.51 | 61.55 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 155.42 | 172.37 | 135.07 | 79.51 | 61.55 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.94 | 0.57 | 1.01 | 2.91 | 0.96 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,896.45 | 163.49 | 4,55,021.88 | 237.82 | 0.71 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,923.75 | 94.67 | 1,57,256.95 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,522.95 | 30.97 | 1,22,988.41 | 1,055.94 | 0.85 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,392.8 | 76.4 | 1,14,822.61 | 469 | 0.83 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,696.1 | 27.12 | 1,11,742.47 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Laxminarayan Moondra
Whole-time Director
Satyanarayan Mundra
Chairman & Independent Directo
C P Rangachar
Managing Director
Sunil L Mundra
Non Executive Director
Sushil Kumar Mundra
Non Executive Director
Jyothi Mundra
Independent Director
Pramod Kasat
Company Sec. & Compli. Officer
Shilpa Burman
Independent Director
Shirish Gundopant Belapure
Independent Director
T Y Prabhu
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Natural Capsules Ltd
Summary
Natural Capsules Limited was incorporated as Public Limited Company established in the year 1993 at Bangalore. The Company is a well-equipped modern manufacturing plant to manufacture Hard Gelatin Capsule shells, Hard Cellulose Capsule shells and Pharmaceutical Dosage Forms in Capsule Dosage Form.The Company meets the statutory requirements as laid down by the authorities in respect to cGMP and cGLP practices. Since its inception, Natural Capsules has ensured to provide turnkey solutions to all its customers. NCL has evolved and strengthened its endeavors by constantly innovating through its excellent products. With a mission to enable Technology Assisted Business Transformation, NCL ensure to deliver the best products with a technological edge.The main objective of the company is to manufacture and market Hard Gelatin Capsule shells and Hard Cellulose Capsule Shells (both printed and unprinted). These capsules are sold in domestic and also exported to several countries. The logical integration of NCL hard shell manufacturing to formulation was initiated in the year 1998.The company is also engaged in formulating the pharmaceutical dosage forms in Capsule dosage form, both Pharma and Neutraceutical Products. The company is fully committed to upgrade its facilities on a continuous basis to meet the requirements of National and International Standards, cGMP and cGLP practices. Natural Capsule has been serving the pharmaceutical industry over a decade, comprising of two units -
Read More
The Natural Capsules Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹304.15 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Natural Capsules Ltd is ₹311.71 Cr. as of 21 Oct ‘24
The PE and PB ratios of Natural Capsules Ltd is 46.47 and 1.97 as of 21 Oct ‘24
The 52-week high/low is the highest and lowest price at which a Natural Capsules Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Natural Capsules Ltd is ₹255 and ₹403 as of 21 Oct ‘24
Natural Capsules Ltd's CAGR for 5 Years at 47.02%, 3 Years at 33.84%, 1 Year at -15.67%, 6 Month at -5.57%, 3 Month at -2.17% and 1 Month at -6.40%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice